CA2153567A1 - Antacid formulation having an improved safety profile - Google Patents
Antacid formulation having an improved safety profileInfo
- Publication number
- CA2153567A1 CA2153567A1 CA002153567A CA2153567A CA2153567A1 CA 2153567 A1 CA2153567 A1 CA 2153567A1 CA 002153567 A CA002153567 A CA 002153567A CA 2153567 A CA2153567 A CA 2153567A CA 2153567 A1 CA2153567 A1 CA 2153567A1
- Authority
- CA
- Canada
- Prior art keywords
- aluminium
- drug
- tablets
- metal phosphates
- alkaline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to aluminium-containing antacids with added phosphate for reducing the absorption of aluminium, and to a process for their preparation.
Description
BAYER AK~ CHAFT 51368 I~v~
Patente K~nzem KS/AB/1108-P
Ant~cid fo ,l,ul~ion havir~ an i~ ved safetv pn~file 5 The invention relates to aluminium-c~ g ~t~rirl~ with added phosph~te for reducing the absorption of alurniniurn, and a process for their ~ ion.
Aluminium-c~)"~ i"~ drug fn~ tions for peroral ~-lmini.~ration, which are chiefly employed as antacids, are very widespread. Since they are often employed as medic~m~nt~ which do not require prescription, i.e. without medical supervision, the 10 greatest possible I~h~ cological safety is particularly important.
Antacids are available in the most diverse peroral drug forms, such as swallowable tablets, chewable tablets, sucking tablets, effervescent tablets, chewing gums, suspensions or as gel drug forms. They often comprise, as active substances, aluminium compounds of di~lcllt compositions, such as, for example, basic aluminium oxides15 and hydroxides, preferably mixed compounds with m~gn~ium, such as, for example, mixtures of aluminium hydroxide and magnesium hydroxide gels and dry gels, layerlattice antacids, m~gn~sium aluminium silicates or aluminium glycoside sulphate complexes, which have an excellent antacid action and, because of their specificcomposition, few side effects. The advantage of aluminium-co"l~;"i"g antacids lies in 20 the ability to establish a therapeutically ideal and constant pH in the stomach.
The absorption of aluminium from these medic~m~nt~ is usually regarded æ non-problematic, but cases exist, such as, for example, in patients suffering from renal insufficiency, where toxic c lmlll~tions of aluminium and diseases resulting th~ n (for example dialysis encephalopathies) have been diagnosed.
Le A 30 302 - Foreign Countries Alnminillrn levels are regarded increasingly more critically against the background of diseases of the central nervous system, so that the smallest possible exposure of the human organism to this light metal is desirable, even though no cases where the normal value of 1-35 ~lg/l of senJm has been exceeded have yet been diagnosed in healthy persons under antacid tre~tm~nt The German p~ lion monographs for the human medicine sector published in 1993 specify a maximum aluminium level of 40 ,ug/l of serum. If this limit value is e~r~J~ c;~ should be intenupted.
As amphoteric compounds, aluminium compounds dissolve in an acid medium significantly better than in a neutral mediur~ In the stom~h, some of the aluminium is therefore always dissolved, with neutralization of the gastric acid. This ability is lltili7~l therapeutically with ~lllminillm-coll~1;llillg antacids. In the case of antacids which comprise only aluminium compounds, the solubility in an acid medium correlates with the antacid activity.
Aluminium compounds are also employed as phosph~te binders for patients with renal 1~ insufficiency, i.e. reduced renal clearance, in order to prevent the adsorption of phosphate from the ~ uill~ l tract and hence hype~hosph~t~mi~ Under long term tre~tm~nt with antacids, however, reduced phosph~te levels have been diagnosed in the serum of patients with normal renal clearance, leading to osteomalacia, hypophosIlh~t~erni~, hypophosphaturia and other phc)sph~te deficiency diseases. To avoid phosphate depletion under long-term tre~tm~nt EP 1 0 040 364 describes synthetic hydrotalcites in which carbonate groups have been replaced by phosphate groups, so that the absorbtion of phosphate from the ga~lloilll~tin~l tract is reduced less.
Two possibilities exist in principle- for keeping the absorption of aluminium from 2~ aluminillm-c~ ;ll;llg antacids low. One possibility is to employ an antacid with the lowest possible content of alllrninillm A second possibility is to supply the aluminium in the most sparingly soluble form possible, in order thus to prevent absorption.
Aluminium/m~n~ium mixed compounds which are fli~tin~lich~cl by a relatively low aluminium content, coupled with an excellent antacid activity, are often employed.
Le A 30 302 - 2 -These compounds react rapidly and have a high acid neutralization capacity, in addition to other substance-specific advantages of this class of substance. Examples of this class of substance are hydrotalcite, magaldrate and the gel antacids of mixtures of magnesium aluminium hydroxides and dry gels thereof. lheir aluminium content S ranges from about 5.1 mg/meq for ~lnminillm m~ium hydroxide mixtures up to 3 mg/meq for hydrotalcite. Regardless of the amount of aluminiurn supplied, however, the upper physiological limit may be reached during Llr~nllr~l of healthy persons, or the level may exceed this limit value of 40 ~lg/l of serurn, especially if disturbances in renal secretion are present, and it should be noted in particular that renal function is 10 often restricted in elderly people.
Sparingly soluble alllmininm compounds include ~lllminiumpho~srh~t~. These are-also directly - employed therapeutically, and show low serurn ~lnrninium levels after~lmini~tration. However, alllminillm phosph~tP~ show a very weak acid neutralization capacity and a poor rate of neutralization during tre~tm~nt so that these fonn~ tions 15 often cannot raise the pH of the stom~l into the therapeutically optimum range of between pH 3 and 5. Di~lo~ltionately large amounts therefore have to be employed, which means that the amount of aluminium supplied is also increased. Ihese compounds are therefore no longer up-to~te for modern antacid L~r~
It has now been found that it has been possible to lower significantly the content of 20 aluminium ions available for absorption, but without reducing the neutralization capacity of the aluminium-c~J~ g antacid, not only when sparingly soluble aluminium phosphates are employed, but also by addition of phosph~tes in the form of other salts to ~lllminium-c~ lg antacids. It has been found here, unexpectedly, that the decrease in absorbable aluminium ions depends on the cations ofthe phosphate salt, 25 allcali metal phosphates having proved to be suitable in particular for non-effervescent formulations. In contrast, ~lk~lin~-earth metal phosphates surprisingly have a significantly more effective action than alkali metal phosphates in effervescentformulations. Various phosphate salts unexpectedly have a significant influence on the extent of the reduction in free alllminillm ions here after siml-l~t~A gastroint~tin~l 30 passage.
LeA30 302 -3 --The free aluminium ions were ~l~t~rminP~ as follows:
The formulation con~t~ tqnt~ are suspended in a defined arnount of water and thesuspension is stirred until the pH is constant. To .simlll~t~ ga~LIo;~ passage, the suspension is titrated with ~imlll~teA gastric juice to pH 1 and then back-titrated with 5 simlll~teA illl~l;ll~l juice to pH 8. The suspension is centrifuged and the content of dissolved alllrninillm is clet~rminf~1 in 20 ml of the clear supr.l~ .ll The percentage content of free aluminium is related to the amount of aluminium employed in the medicament and represents the discharge of ~Illnninium from the medicament during simlll~teA gastrointestin~l passage.
Co.Dlilu~.lt Weight (mg) F~ee 1. Hydrotalcite 500 0.22 2. Hydrotalcite 500 0.23 Tricalcium phosphate 257 3. Hydrotalcite 500 0.04 Potassium phosphate 352 4. Hydrotalcite 500 0.13 Trim~ium phosphate 224 5. Hydrotalcite 500 93.9 Citric acid 240 Sodium bicarbonate 1,344 6. Hydrotalcite 500 63.20 Citric acid 240 Sodium carbonate 1,344 Potassium dihydrogen phosphate1,088 7. Hydrotalcite 500 9.2 Citric acid 384 Sodiurn bicarbonate 504 Calciurn phosphate 930 The corresponding phosphate salt for lowering the discharge of aluminium is added to the corresponding antacid recipes by customary methods and without expensive 20 processing steps. The amount of phosphate added depends here on the amount ofaluminium released in the gastrointestin~l tract, that is to say the aluminium content of LeA30 302 -4-the aluminium compound, and should be approximately equivalent to the amount of aluminium ions released in the ga~lloi~ l tract. An amount of phosphate which isequivalent to 0.5 to 1.5 times the amount of aluminium processed in the forrnulation is preferably chosen.
Embodiment examples Example 1 Hydrotalcite 500 mg Potassium phosphate 250 mg Corn starch 240 mg Colloidal silicic acid 5 mg Magnesium stearate S mg Hydrotalcite, potassium phosphate and corn starch are gr~mll~te~l with water in a rotory granulator. The granules are dried in a drying cabinet, classified and mixed with the colloidal silicic acid and the m~gnP~ium stearate, and the mixture is pressed to tablets of 1 g in weight.
Example 2 Aluminium hydroxide 250 mg Magnesium hydroxide 250 mg Trim~gn~ium phosphate 250 mg Avicel 195 mg Aerosil S mg Talc 50 mg Tlle constituents are all weighed into a suitable mixer and mixed thoroughly, and the mixture is then pressed directly to tablets of 1 g in weight.
Example 3 Alm~gate 500 mg Potassium phosphate 350 mg Lactose 270 mg Le A 30 302 - 5 -. ~
~ 2153567 The ~Im:~tç7 potassium phosph~te and lactose are weighed into a dish granulator and gr~n~ te~l with a saturated lactose solution. Ihe granules are dried and classified and then packed as individual doses of 1 g in polypropylene bags.
Example 4 Hydrotalcite 500 mg Trimagnesium phosphate500 mg Citric acid 1,120 mg Sodium bicarbonate 1,344 mg Polyethylene glycol 600046 mg 10 The citric acid and sodium bicarbonate are gr~n~ tPA with an ethanol/water mixture, the hydrotalcite and the trim~gnP-sium ~ho~r)h~te are admixed, and finally the polyethylene glycol 6000 is mixed in and the mixture is pressed to tablets of 3,500 mg under climatically controlled conditions.
Le A 30 302 - 6 -
Patente K~nzem KS/AB/1108-P
Ant~cid fo ,l,ul~ion havir~ an i~ ved safetv pn~file 5 The invention relates to aluminium-c~ g ~t~rirl~ with added phosph~te for reducing the absorption of alurniniurn, and a process for their ~ ion.
Aluminium-c~)"~ i"~ drug fn~ tions for peroral ~-lmini.~ration, which are chiefly employed as antacids, are very widespread. Since they are often employed as medic~m~nt~ which do not require prescription, i.e. without medical supervision, the 10 greatest possible I~h~ cological safety is particularly important.
Antacids are available in the most diverse peroral drug forms, such as swallowable tablets, chewable tablets, sucking tablets, effervescent tablets, chewing gums, suspensions or as gel drug forms. They often comprise, as active substances, aluminium compounds of di~lcllt compositions, such as, for example, basic aluminium oxides15 and hydroxides, preferably mixed compounds with m~gn~ium, such as, for example, mixtures of aluminium hydroxide and magnesium hydroxide gels and dry gels, layerlattice antacids, m~gn~sium aluminium silicates or aluminium glycoside sulphate complexes, which have an excellent antacid action and, because of their specificcomposition, few side effects. The advantage of aluminium-co"l~;"i"g antacids lies in 20 the ability to establish a therapeutically ideal and constant pH in the stomach.
The absorption of aluminium from these medic~m~nt~ is usually regarded æ non-problematic, but cases exist, such as, for example, in patients suffering from renal insufficiency, where toxic c lmlll~tions of aluminium and diseases resulting th~ n (for example dialysis encephalopathies) have been diagnosed.
Le A 30 302 - Foreign Countries Alnminillrn levels are regarded increasingly more critically against the background of diseases of the central nervous system, so that the smallest possible exposure of the human organism to this light metal is desirable, even though no cases where the normal value of 1-35 ~lg/l of senJm has been exceeded have yet been diagnosed in healthy persons under antacid tre~tm~nt The German p~ lion monographs for the human medicine sector published in 1993 specify a maximum aluminium level of 40 ,ug/l of serum. If this limit value is e~r~J~ c;~ should be intenupted.
As amphoteric compounds, aluminium compounds dissolve in an acid medium significantly better than in a neutral mediur~ In the stom~h, some of the aluminium is therefore always dissolved, with neutralization of the gastric acid. This ability is lltili7~l therapeutically with ~lllminillm-coll~1;llillg antacids. In the case of antacids which comprise only aluminium compounds, the solubility in an acid medium correlates with the antacid activity.
Aluminium compounds are also employed as phosph~te binders for patients with renal 1~ insufficiency, i.e. reduced renal clearance, in order to prevent the adsorption of phosphate from the ~ uill~ l tract and hence hype~hosph~t~mi~ Under long term tre~tm~nt with antacids, however, reduced phosph~te levels have been diagnosed in the serum of patients with normal renal clearance, leading to osteomalacia, hypophosIlh~t~erni~, hypophosphaturia and other phc)sph~te deficiency diseases. To avoid phosphate depletion under long-term tre~tm~nt EP 1 0 040 364 describes synthetic hydrotalcites in which carbonate groups have been replaced by phosphate groups, so that the absorbtion of phosphate from the ga~lloilll~tin~l tract is reduced less.
Two possibilities exist in principle- for keeping the absorption of aluminium from 2~ aluminillm-c~ ;ll;llg antacids low. One possibility is to employ an antacid with the lowest possible content of alllrninillm A second possibility is to supply the aluminium in the most sparingly soluble form possible, in order thus to prevent absorption.
Aluminium/m~n~ium mixed compounds which are fli~tin~lich~cl by a relatively low aluminium content, coupled with an excellent antacid activity, are often employed.
Le A 30 302 - 2 -These compounds react rapidly and have a high acid neutralization capacity, in addition to other substance-specific advantages of this class of substance. Examples of this class of substance are hydrotalcite, magaldrate and the gel antacids of mixtures of magnesium aluminium hydroxides and dry gels thereof. lheir aluminium content S ranges from about 5.1 mg/meq for ~lnminillm m~ium hydroxide mixtures up to 3 mg/meq for hydrotalcite. Regardless of the amount of aluminiurn supplied, however, the upper physiological limit may be reached during Llr~nllr~l of healthy persons, or the level may exceed this limit value of 40 ~lg/l of serurn, especially if disturbances in renal secretion are present, and it should be noted in particular that renal function is 10 often restricted in elderly people.
Sparingly soluble alllmininm compounds include ~lllminiumpho~srh~t~. These are-also directly - employed therapeutically, and show low serurn ~lnrninium levels after~lmini~tration. However, alllminillm phosph~tP~ show a very weak acid neutralization capacity and a poor rate of neutralization during tre~tm~nt so that these fonn~ tions 15 often cannot raise the pH of the stom~l into the therapeutically optimum range of between pH 3 and 5. Di~lo~ltionately large amounts therefore have to be employed, which means that the amount of aluminium supplied is also increased. Ihese compounds are therefore no longer up-to~te for modern antacid L~r~
It has now been found that it has been possible to lower significantly the content of 20 aluminium ions available for absorption, but without reducing the neutralization capacity of the aluminium-c~J~ g antacid, not only when sparingly soluble aluminium phosphates are employed, but also by addition of phosph~tes in the form of other salts to ~lllminium-c~ lg antacids. It has been found here, unexpectedly, that the decrease in absorbable aluminium ions depends on the cations ofthe phosphate salt, 25 allcali metal phosphates having proved to be suitable in particular for non-effervescent formulations. In contrast, ~lk~lin~-earth metal phosphates surprisingly have a significantly more effective action than alkali metal phosphates in effervescentformulations. Various phosphate salts unexpectedly have a significant influence on the extent of the reduction in free alllminillm ions here after siml-l~t~A gastroint~tin~l 30 passage.
LeA30 302 -3 --The free aluminium ions were ~l~t~rminP~ as follows:
The formulation con~t~ tqnt~ are suspended in a defined arnount of water and thesuspension is stirred until the pH is constant. To .simlll~t~ ga~LIo;~ passage, the suspension is titrated with ~imlll~teA gastric juice to pH 1 and then back-titrated with 5 simlll~teA illl~l;ll~l juice to pH 8. The suspension is centrifuged and the content of dissolved alllrninillm is clet~rminf~1 in 20 ml of the clear supr.l~ .ll The percentage content of free aluminium is related to the amount of aluminium employed in the medicament and represents the discharge of ~Illnninium from the medicament during simlll~teA gastrointestin~l passage.
Co.Dlilu~.lt Weight (mg) F~ee 1. Hydrotalcite 500 0.22 2. Hydrotalcite 500 0.23 Tricalcium phosphate 257 3. Hydrotalcite 500 0.04 Potassium phosphate 352 4. Hydrotalcite 500 0.13 Trim~ium phosphate 224 5. Hydrotalcite 500 93.9 Citric acid 240 Sodium bicarbonate 1,344 6. Hydrotalcite 500 63.20 Citric acid 240 Sodium carbonate 1,344 Potassium dihydrogen phosphate1,088 7. Hydrotalcite 500 9.2 Citric acid 384 Sodiurn bicarbonate 504 Calciurn phosphate 930 The corresponding phosphate salt for lowering the discharge of aluminium is added to the corresponding antacid recipes by customary methods and without expensive 20 processing steps. The amount of phosphate added depends here on the amount ofaluminium released in the gastrointestin~l tract, that is to say the aluminium content of LeA30 302 -4-the aluminium compound, and should be approximately equivalent to the amount of aluminium ions released in the ga~lloi~ l tract. An amount of phosphate which isequivalent to 0.5 to 1.5 times the amount of aluminium processed in the forrnulation is preferably chosen.
Embodiment examples Example 1 Hydrotalcite 500 mg Potassium phosphate 250 mg Corn starch 240 mg Colloidal silicic acid 5 mg Magnesium stearate S mg Hydrotalcite, potassium phosphate and corn starch are gr~mll~te~l with water in a rotory granulator. The granules are dried in a drying cabinet, classified and mixed with the colloidal silicic acid and the m~gnP~ium stearate, and the mixture is pressed to tablets of 1 g in weight.
Example 2 Aluminium hydroxide 250 mg Magnesium hydroxide 250 mg Trim~gn~ium phosphate 250 mg Avicel 195 mg Aerosil S mg Talc 50 mg Tlle constituents are all weighed into a suitable mixer and mixed thoroughly, and the mixture is then pressed directly to tablets of 1 g in weight.
Example 3 Alm~gate 500 mg Potassium phosphate 350 mg Lactose 270 mg Le A 30 302 - 5 -. ~
~ 2153567 The ~Im:~tç7 potassium phosph~te and lactose are weighed into a dish granulator and gr~n~ te~l with a saturated lactose solution. Ihe granules are dried and classified and then packed as individual doses of 1 g in polypropylene bags.
Example 4 Hydrotalcite 500 mg Trimagnesium phosphate500 mg Citric acid 1,120 mg Sodium bicarbonate 1,344 mg Polyethylene glycol 600046 mg 10 The citric acid and sodium bicarbonate are gr~n~ tPA with an ethanol/water mixture, the hydrotalcite and the trim~gnP-sium ~ho~r)h~te are admixed, and finally the polyethylene glycol 6000 is mixed in and the mixture is pressed to tablets of 3,500 mg under climatically controlled conditions.
Le A 30 302 - 6 -
Claims (6)
1. Aluminium-containing drug formulation for peroral administration having a reduced absorption of aluminium ions, characterized in that it comprises 0.5 to 1.5 molar equivalent of phosphate.
2. Drug formulation according to Claim 1 in the form of swallowable tablets, chewable tablets, sucking tablets, effervescent tablets, chewing gums, suspensions and gel drug forms for oral use.
3. Drug formulation according to Claim 1, characterized in that alkali metal phosphates are employed in non-effervescent drug forms and alkaline-earth metal phosphates are employed in effervescent drug forms.
4. Drug forms according to Claim 1, characterized in that they comprise aluminium-containing antacids from the group consisting of aluminium hydroxides, aluminium hydroxide/magnesium mixed compounds, aluminium magnesium silicates, aluminium-containing compounds having a crystalline structure or basic aluminium glycoside sulphate complexes as the active compound.
5. Use of alkali metal and alkaline-earth metal phosphates for the preparation of aluminium-containing drug formulations for oral administration, for reducing the absorption of aluminium.
6. Process for the preparation of drug formulations according to Claim 1, characterized in that at least one aluminium-containing active compound is mixed with an amount of alkali metal or alkaline-earth metal phosphates approximately equivalent to the amount of aluminium used, if appropriate using customary auxiliaries and excipients.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4424675.7 | 1994-07-13 | ||
| DE4424675A DE4424675A1 (en) | 1994-07-13 | 1994-07-13 | Antacid preparation with improved safety profile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2153567A1 true CA2153567A1 (en) | 1996-01-14 |
Family
ID=6523023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002153567A Abandoned CA2153567A1 (en) | 1994-07-13 | 1995-07-10 | Antacid formulation having an improved safety profile |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0692255A3 (en) |
| JP (1) | JPH0840917A (en) |
| KR (1) | KR960003733A (en) |
| CA (1) | CA2153567A1 (en) |
| DE (1) | DE4424675A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3329564A (en) * | 1965-06-28 | 1967-07-04 | Parke Davis & Co | Antacid preparations and means of producing the same |
| JPS56158716A (en) | 1980-05-14 | 1981-12-07 | Kyowa Chem Ind Co Ltd | Antacid preparation |
| DK179687D0 (en) * | 1987-04-08 | 1987-04-08 | Farma Food As | PREPARATION |
| AU6426994A (en) * | 1993-03-16 | 1994-10-11 | Synepos Aktiengesellschaft | Aluminium containing pharmaceutical preparation with controlled release |
-
1994
- 1994-07-13 DE DE4424675A patent/DE4424675A1/en not_active Withdrawn
-
1995
- 1995-06-30 EP EP95110224A patent/EP0692255A3/en not_active Withdrawn
- 1995-07-10 CA CA002153567A patent/CA2153567A1/en not_active Abandoned
- 1995-07-10 JP JP7195718A patent/JPH0840917A/en active Pending
- 1995-07-12 KR KR1019950020455A patent/KR960003733A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE4424675A1 (en) | 1996-01-18 |
| EP0692255A3 (en) | 1997-07-23 |
| KR960003733A (en) | 1996-02-23 |
| EP0692255A2 (en) | 1996-01-17 |
| JPH0840917A (en) | 1996-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4650669A (en) | Method to make effervescent calcium tablets and calcium tablets produced thereby | |
| EP2194972B1 (en) | Mixed metal compounds used as antacids | |
| US4956386A (en) | Pharmaceutical compositions and process for their preparation | |
| JP2008516971A (en) | Phosphate binder that reduces the burden of tablets | |
| US4115553A (en) | Antacid tablets | |
| CA2376017C (en) | Potassium calcium citrate compositions and methods for production | |
| US2477080A (en) | Antacid preparation | |
| HU193524B (en) | Process for production of stabil, colloidially soluable in water, containing bismuth compositions | |
| WO1992000102A1 (en) | Novel treatment | |
| EP0040521B1 (en) | Antacid material based on magnesium aluminium hydroxide and the preparation thereof | |
| AU2013346766A1 (en) | Effervescent tablet | |
| CA2153567A1 (en) | Antacid formulation having an improved safety profile | |
| JPS6136222A (en) | Remedy for hyperphosphatemia | |
| US20030077331A1 (en) | Calcium glutarate supplement and phosphorus binder | |
| US4221783A (en) | Composition and method for the treatment of duodenal ulcers, gastritis and gastro-duodenitis | |
| JP3542190B2 (en) | Method for producing calcium-casein phosphopeptide preparation, food for inhibiting bone mineral loss and agent for inhibiting bone mineral loss | |
| US3655883A (en) | Water soluble magnesium-aluminum antacid composition | |
| CN114832020B (en) | Pharmaceutical composition for preventing and treating child developmental disorder and preparation method thereof | |
| JPH07103037B2 (en) | Rehydratable magaldrate composition | |
| JP3662016B2 (en) | Medicine for prevention and / or treatment of constipation and symptoms associated with constipation | |
| US3208906A (en) | Glycine-stabilized aluminum hydroxidemagnesium compound codried gel antacids and process of making the same | |
| EP0715520B1 (en) | Use of a suspension based on sucralphate gel as antacid | |
| CA1203177A (en) | Modified clays, preparation thereof and therapeutical compositions containing the same | |
| JP2000219625A (en) | Medicinal composition | |
| JP3905982B2 (en) | Antacid composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |